EvanthiaGalanisMD

PubMed

• 2 citations
  A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
  Benjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, Raymond Y Huang, Javier E Villanueva-Meyer
  AJNR. American Journal of Neuroradiology. 2024-12-09
• Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
  Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini
  JAMA Oncology. 2024-12-01
• Correlative Science in the Cooperative Group System: Re-Engineering for Success.
  Peter J O'Dwyer, Norman Wolmark, Douglas S Hawkins, Mitchell Schnall, Janet Dancey
  Journal of Clinical Oncology. 2024-11-20

Journal Articles

• Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma  
  Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E, Cancer Gene Ther, 1/14/2014
• New validated prognostic models and prognostic calculators in patients with low grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NC...  
  Gorlia T, Wenting W, Wang M, Baumert B, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den, Neuro Oncol, 1/1/2013
• Specific targeting of human interleukin (il)-13 receptor alpha 2-positive cells with lentiviral vectors displaying il-13  
  Ou W, Marino MP, Suzuki A, Joshi B, Husain SR, Maisner A, Galanis E, Puri RK, Reiser J, Human Gene Therapy Methods, 1/1/2012
• Measles virotherapy in prostate cancer treatment: A novel antitumor approach  
  Msaouel P, Galanis E, Future Virol, 1/1/2009
• Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity  
  Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E, Mol Ther, 1/1/2008
• Percutaneous osteoplasty for pelvic and spine metastases  
  Papagelopoulos PJ, Mavrogenis AF, Kelekis AD, Katonis P, Galanis EC, Wenger DE, Sim FH, Soucacos PN, Orthopedics, 1/1/2006
• Lateral malleolus en bloc resection and ankle reconstruction for malignant tumors  
  Papagelopoulos PJ, Savvidou OD, Mavrogenis AF, Galanis EC, Shaughnessy WJ, Unni KK, Sim FH, Clin Orthop Relat Res Relat Res, 1/1/2005
• Malignant fibrous histiocytoma of bone associated with type-1 neurofibromatosis A case report  
  Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Chloros GD, Papaparaskeva KT, J Bone Joint Surg Am, 1/1/2005
• Sindbis vectors: illuminating the path to ovarian cancer therapy  
  Peng KW, Galanis E, Gene Ther, 1/1/2005
• Erdheim-Chester disease: a rare lipoid granulomatosis  
  Savvidou OD, Papagelopoulos PJ, Galanis EC, Inwards CY, Wenger DE, Sim FH, Orthopedics, 1/1/2004
• Malignant fibrous histiocytoma of bone Diagnosis and Treatment  
  Savvidou OD, Papagelopoulos PJ, Galanis EC, Boscainos PJ, Papdopoulos EC, Triantafillopoulos IK, Ostoun, 1/1/2003
• Epidemiological data, diagnosis and treatment of Ewing sarcoma  
  Papadopoulos EC, Papagelopoulos PJ, Galanis EC, Savvidou OD, Karavolias CE, Mavrogenis AF, Ostoun, 1/1/2003
• Current concepts on treatment and prognosis of osteosarcoma  
  Savvidou OD, Papagelopoulos PJ, Galanis EC, Papdopoulos HC, Boscainos PJ, Karavolias CE, Ostoun, 1/1/2003
• Molecular biology of bone tumors  
  Mavrogenis AF, Papagelopoulos PJ, Galanis EC, Psicharis IP, Savvidou OD, Karavolias C, Linardaki E, Ostoun, 1/1/2003
• Periosteal chondrosarcoma  
  Papagelopoulos PJ, Galanis EC, Boscainos PJ, Bond JR, Unni KK, Sim FH, Orthopedics, 1/1/2002
• Periosteal osteosarcoma  
  Papagelopoulos PJ, Galanis E, Sim FH, Unni KK, Orthopedics, 1/1/1999
• Mayo Clinic tumor rounds: periosteal osteosarcoma  
  Papagelopoulos PJ, Galanis E, Sim FH, Unni KK, Orthopedics, 1/1/1999
• Diagnosis in oncology  
  Skarin A, Galanis E, Kvols LK, Rubin J, J Clin Oncol, 1/1/1998
• Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia  
  Galanis E, Hartmann LC, Topics Support Care Oncol, 1/1/1998
• Cancer gene therapy: an overview based on the first annual Meeting of the American Society of Gene Therapy  
  Galanis E, Tumor Targeting, 1/1/1998
• Infection around joint replacements in patients who have a renal or liver transplantation  
  Papagelopoulos PJ, Hay JE, Galanis E, Morrey BF, J Bone Joint Surg Am, 1/1/1998
• Aneurysmal bone cysts of the cervical spine  
  Papagelopoulos P, Galanis E, Shaughnessy WJ, Currier BL, Sim FH, Unni KK, Acta Orthopaedica Hellenica, 1/1/1994
• Infectious endocarditis: Prognosis, prophylaxis, treatment  
  Galanis E, Topics in Cardiology, 1/1/1989
• Join now to see all

Books/Book Chapters

• Gene and Cell Therapy: Therapeutic Mechanisms and Strategies 
  Chapter: Oncolytic Measles Virus-based delivery systems. 
  Page 157 - 174Msaouel P, Galanis EEditors: N.S. Templeton.CRC Press, Boca RatonEdition 4th,2014
• Oncolytic Viruses: Methods and Protocols 
  Chapter: Oncolytic measles virus retargeting by ligand display. 
  Page 141 - 162Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis EEditors: D.H. Kirn, Ta-Chiang Liu and S.H. Thorne.Humana Press Inc.2012
• Brain Tumors: Practical Guide to Diagnosis and Treatment 
  Chapter: Malignant central nervous system neoplasms of mesenchymal origin. 
  Page 325 - 340Galanis EEditors: Baehring JM, Piepmeier JM.Informa Healthcare, New York2007
• Novel Anticancer Agents 
  Chapter: Cancer gene therapy clinical trials. From the bench to the clinic. 
  Page 379 - 390Galanis E2006
• Oncology: An Evidence-Based Approach 
  Chapter: Central nervous system tumors. 
  Page 487 - 505Rao RD, Brown PD, Giannini C, Maher CO, Meyer FB, Galanis E, Erickson BJ, Buckner JCEditors: Chang AE, et al.Springer, New York2006
• Neurological Therapeutics: Principles and Practice 
  Chapter: Diffuse cerebral gliomas in adults. 
  Page 832 - 853Galanis E, Buckner JCEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
• Viral Therapy of Human Cancers 
  Chapter: Measles virus: improving natural oncolytic properties by genetic engineering. 
  Page 459 - 480Springfeld C, Fielding A, Peng KW, Galanis E, Russell SJ, Cattaneo REditors: Sinkovics JG, Horvath JC.Marcel Dekker, New York2005
• Disorders of Bone and Mineral Metabolism 
  Chapter: Primary cystic and neoplastic diseases of bone. 
  Page 1021 - 1050Papagelopoulos PJ, Turcotte RE, Galanis EC, Wold LE, Sim FHEditors: Coe FL, Favus MJ.Lippincott Williams & Wilkins, PhiladelphiaEdition 2nd,2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Wilms' tumor. 
  Page 361 - 363Papagelopoulos PJ, Galanis EC, Arndt CAS, Sim FHEditors: Bulstrode C, et al.Oxford University Press, Oxford2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Metastatic neuroblastoma. 
  Page 358 - 361Papagelopoulos PJ, Galanis EC, Arndt CAS, Sim FHEditors: Bulstrode C, et al.Oxford University Press, Oxford2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Metastatic bone disease due to carcinoma. 
  Page 340 - 358Papagelopoulos PJ, Galanis EC, Sim FHEditors: Bulstrode C, et al.Oxford University Press, Oxford2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Malignant fibrous histiocytoma of bone. 
  Page 288 - 294Papagelopoulos PJ, Galanis EC, McDonald DJ, Sim FHEditors: Bulstrode C, et al.Oxford University Press, Oxford2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Metastic neoplasms: Metastatic bone disease due to carcinoma. 
  Page 340 - 358Papagelopoulos PJ, Galanis E, Sim FHEditors: C. Bulstrode, et al.Oxford University Press2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Osteoblastoma. 
  Page 157 - 161Papagelopoulos PJ, Galanis E, Ruggieri P, Sim FHEditors: C. Bulstrode, et al.Oxford University Press2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Malignant fibrous istiocytoma of bone. 
  Page 288 - 294Papagelopoulos PJ, Galanis E, McDonald D, Sim FHEditors: C. Bulstrode, et al.Oxford University Press2002
• Oxford Textbook of Orthopaedics and Trauma 
  Chapter: Fibrosarcoma of bone. 
  Page 283 - 288Papagelopoulos PJ, Galanis E, McDonald D, Sim FHEditors: C. Bulstrode, et al.Oxford University Press2002
• OKU: Musculoskeletal Tumors 
  Chapter: Supportive measures: Carcinoma metastatic to bone. 
  Page 331 - 341Galanis EEditors: L.R. Menendez.American Association of Orthopedic Surgeons2001
• Clinical Radiation Oncology 
  Chapter: High-grade gliomas. 
  Page 355 - 378Algan O, Nelson DF, Dinapoli RP, Galanis E, Raffel C, Parisi JE, Buckner JC, Jenkins RBEditors: Gunderson LL, Tepper JE.Churchill Livingstone, New York2000
• Honorary Edition for Professor Emeritus B. Golematis 
  Chapter: Cancer gene therapy: From basic research to clinical practice. 
  Page 49 - 53Galanis E1999
• Molecular Biology in Cancer Medicine 
  Chapter: Brain tumors. 
  Page 273 - 286Galanis E, James CDEditors: Kurzrock R, Talpaz M.Martin Dunitz, London1999
• Oxford Textbook of Orthopedics and Trauma 
  Chapter: Fibrosarcoma of bone. 
  Papagelopoulos PJ, Galanis EC, McDonald DJ, Sim FHOxford University Press, Oxford, England1996
• Hononary Edition for Professor Emeritus G Daikos 
  Chapter: Ancient Greek medicine: from Homer to Hippocrates. 
  Galanis E1988
• Join now to see all

Abstracts/Posters

• Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
  Evanthia Galanis, MD, 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2014
• Gene expression profile of innate immune anti-viral factors in ovarian cancer patients treated with oncolytic measles virus.
  Iankov I, Kurokawa C, Middha S, Aderca I, Allen C, Keeney G, Federspiel M, Maurer M, Atherton P, Kalli K, Hartmann L, Galanis E, Mol Ther, 1/1/2014
• Modulation of innate immunity with ctla4 blockade in measles virotherapy for glioblastoma.
  Hardcastle J, Feng J, Kurokawa C, Domingo-Musibay E, Allen C, Johnson A, Galanis E, Mol Ther, 1/1/2014
• Pre-existing antiviral state can impact oncolytic infection in glioblastoma patients treated with oncolytic measles virus.
  Kurokawa C, Iankov I, Aderca I, Petell C, Middha S, Giannini C, Parney I, Galanis E, Mol Ther, 1/1/2014
• Mir-128 and mir-31 regulates pvrl4 and oncolytic measles virus infectivity.
  Geekiyanage H, Galanis E, Mol Ther, 1/1/2014
• Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
  Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Bucker JC, Ligon KL, Ballman KV, Moore DF, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman..., J Clin Oncol, 1/1/2014
• Aurora-A mitotic kinase and induction of endocrine resistance through downregulation of ERA expression in initially ERA+ breast cancer cells.
  Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Haddad TC, Degnim AC, Lange CA, Ingle JN, Galanis E, D'Assoro A, J Clin Onc, 1/1/2014
• Validation of rano criteria: contribution with T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.
  Yi-kun Huang R, Rahman R, Pope WB, Ellingson BM, Anderson SK, Felten SJ, Ballman KV, Wu W, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Cloughesy TF, Wen PY, J Clin Oncol, 1/1/2014
• An update on high-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  Wilcox RE, Litzow MR, Galanis E, Gill P, Buckner JC, J Clin Oncol, 1/1/2014
• A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
  Kurzrock R, Galanis E, Johnson DR, Kansra V, Wilcoxen K, Mcclure T, Martell RE, Agarwal S, J Clin Oncol, 1/1/2014
• Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final res...
  Evanthia Galanis, MD, 2013 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2013
• Preliminary results-"a phase i trial of oncolytic measles virotherapy in mesothelioma" investigating the intrapleural administration of the modified vaccine strain mea...
  Peikert T, Molina J, Aderca I, Albelda S, Carlson S, Lowe V, Maldonado F, Mandrekar S, Patel M, Roden A, Van Keulen V, Kratzke R, Galanis E, J Thorac Oncol, 1/1/2013
• The neurologic assessment in neuro-oncology (nano) scale: a tool to assess neurologic function for integration in the radiologic assessment in neuro-oncology (rano) cr...
  Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, MacDonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent..., Neuro-oncol, 1/1/2013
• Relationship between overall survival and progression-based endpoints in bev-included recurrent glioblastoma multiforme trials.
  Wu WT, Galanis E, Wen P, Das A, Fine H, Cloughesy T, Sargent D, Neuro-oncol, 1/1/2013
• Gene expression profiling identifies predictive markers of response to oncolytic measles virus therapy.
  Iankov I, Allen C, Parney I, Giannini C, Galanis E, Mol Ther, 1/1/2013
• Efficacy of measles virotherapy in osteosarcoma.
  Domingo Musibay E, Allen C, Iankov ID, Hardcastle JJ, Galanis E, Mol Ther, 1/1/2013
• Intraperitoneal (ip) administration of an oncolytic measles virus (mv) strain expressing the sodium iodine symporter gene in patients (pts) with advanced ovarian cance...
  Galanis E, Atherton P, Dowdy S, Cliby W, Haluska P, Long H, Aderca I, Knutson K, Block M, Federspiel M, Russell S, Peng KW, Hartmann L, Mol Ther, 1/1/2013
• Modulation of innate immunity with the anti-ctla4 antibody ipilimumab (ipi) in measles virotherapy for glioblastoma.
  Hardcastle JJ, Geekiyanage H, Domingo Musibay E, Allen C, Fang J, Johnson A, Galanis E, Mol Ther, 1/1/2013
• Data in support of the clinical use of adipose derived msc: growth, storage, function and safety.
  Dietz AB, Padley DJ, Butler GW, Anderson JM, Sarr MG, Windebank AJ, Textor SC, Kudva YC, Galanis E, Peng K, Gastineau DA, Cytotherapy, 1/1/2013
• SMAD5 expression and inhibition of the mitotic kinase aurora-A on sensitivity of breast cancer cells to chemotherapy.
  Opyrchal M, Iankov I, Ingle JN, Salisbury JL, Galanis E, D'Assoro A, J Clin Oncol, 1/1/2013
• NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and ...
  Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Giannini C, Erickson BJ, Buckner JC, J Clin Oncol, 1/1/2013
• Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final res...
  Galanis E, Sarkaria JN, Anderson SK, Wu W, Jaeckle KA, Giannini C, Buckner JC, Wen PY, Alliance for, J Clin Oncol, 1/1/2013
• Pilocytic astrocytoma survival in adults: analysis of the surveillance, epidemiology, and end results program of the national cancer institute.
  Johnson D, Brown P, Galanis E, Hammack J, Neurology, 1/26/2012
• Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemo-radiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final res...
  Laack NN, Galanis E, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Jaeckle KA, Sarkaria JN, J Clin Oncol, 1/20/2012
• The aurora a kinase inhibitor MLN8237 significantly enhances the antitumor activity of oncolytic measles virus derivatives in the treatment of glioblastoma.
  Allen C, Iankov I, Opyrchal M, Keith LAG, Schroeder MA, Sarkaria JN, Ecsedy J, Galanis E, Mol Ther, 1/1/2012
• Join now to see all

Lectures

• Integrating Tumor Genomics Including WHO Guidelines Into Novel Clinical Trial Designs 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• "Measles and Vesicular Stomatitis Virus Strains as Novel Oncolytic Platforms" 
  Barcleona, Spain - 1/1/2014
• "Cooperative Group Update" 
  Miami, FL - 1/1/2014
• "Role of Antiangiogenic Therapy Post RTOG 0825/AVAglio" 
  Miami, FL - 1/1/2014
• "Recurrent GBM Unmet Needs and the Quest for Hope" 
  Barcelona, Spain - 1/1/2014
• "Immunotherapeutic potential of oncolytic virotherapy approaches: the paradigm of engineered" 
  Nantes, France - 1/1/2014
• "Novel Approaches in Phase II Trial Design in Neurooncology" 
  San Francisco, CA - 1/1/2013
• "Newly Diagnosed Glioblastoma: Current Standards and Unmet Needs" 
  Amsterdam, Netherlands - 1/1/2013
• "Clinical Experience with Engineered Oncolytic Measles Virus Strains" 
  Bethesda, MD - 1/1/2013
• "Oncolytic Measles Virus Strains in Cancer Treatment Trials: An update" 
  Salt Lake City, UT - 1/1/2013
• "Oncolytic Measles Strains in GBM Treatment: An Update" 
  Washington, DC - 1/1/2012
• "Oncolytic Viruses: Clinical Trial Updates" 
  Washington, DC - 1/1/2012
• "Challenges in Phase II Trial Design in Neurooncology" 
  Orange County, CA - 1/1/2011
• "Preclinical Development and Clinical Testing of Oncolytic Measles Virus" 
  Orange County, CA - 1/1/2011
• "Virotherapy Trials and the Brain SPORE Program" 
  Washington, DC - 1/1/2011
• "Personalizing Cancer Treatment: Targeted Therapeutics in Oncology" 
  Athens, Greece - 1/1/2011
• "Clinical Translation of Oncolytic Measles Strains: Ongoing Trials and Future Directions" 
  Las Vegas, NV - 1/1/2011
• "Pre-clinical Development and Clinical Testing of Oncolytic Measles Virus" 
  Anaheim, CA - 1/1/2011
• "NCCTG Phase II Trial of Bevacizumab in Combination with Sorafenib (BEV/SOR) in Recurrent Glioblastoma (rGBM)" 
  Anaheim, CA - 1/1/2011
• "Phase II Trial of Vorinostat in Combination with Bortezomib in Recurrent Glioblastoma Multiforme: a North Central Cancer Treatment Group Study" 
  Montreal, Quebec, Canada - 1/1/2011
• "Neurooncology" 
  Rochester, MN - 1/1/2011
• "Current Clinical Trials of Oncolytic Measles Strains and Future Steps" 
  Rochester, MN - 1/1/2011
• "Neurooncology Update" 
  Rochester, MN - 1/1/2011
• "Clinical Translation of Oncolytic Measles Strains as Cancer Therapeutics: Promises and Challenges" 
  The Children's Hospital of Philadelphia, Philadelphia, PA - 1/1/2010
• Mentor: "From Homer to 21st Century Clinical Research" 
  Chicago, IL - 1/1/2010
• Join now to see all